Epidemiology, pathophysiology and therapeutic implications of lipoprotein(a) in kidney disease

Expert Review of Cardiovascular Therapy

Volumn 2, Issue 5, 2004, Pages 729-743

  Kronenberg, Florian ^a,b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Apolipoprotein(a) polymorphism; Atherosclerosis; Dialysis; Kidney disease; Lipoprotein(a); Niacin; Risk stratification; Statin

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; APOLIPOPROTEIN A; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; CORTICOTROPIN; CREATININE; ESTRADIOL; FIBRIC ACID DERIVATIVE; GESTAGEN; GLYCOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; LIPOPROTEIN A; LONG ACTING DRUG; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; NICOTINIC ACID; NICOTINIC ACID DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; OXIDIZED LOW DENSITY LIPOPROTEIN; PLASMIN; RALOXIFENE; TAMOXIFEN; TIBOLONE; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; VERY LOW DENSITY LIPOPROTEIN RECEPTOR;

ATHEROSCLEROSIS; BREAST CANCER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY OBSTRUCTION; CHRONIC KIDNEY DISEASE; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG ERUPTION; DYSLIPOPROTEINEMIA; FLUSHING; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; HEREDITY; HORMONE SUBSTITUTION; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN SYNTHESIS; LIVER TOXICITY; MORTALITY; NAUSEA; NEPHROTIC SYNDROME; NONHUMAN; PREDICTION; PROTEIN DEGRADATION; PROTEIN POLYMORPHISM; PROTEINURIA; PRURITUS; REVIEW; RISK FACTOR; SIDE EFFECT;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; HUMANS; KIDNEY DISEASES; LIPOPROTEIN(A); NIACIN; POLYMORPHISM, GENETIC; RISK ASSESSMENT;

EID: 4544253569     PISSN: 14779072     EISSN: None     Source Type: Journal    
DOI: 10.1586/14779072.2.5.729     Document Type: Review

References (125)

1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am. J. Kidney Dis. 32(Suppl. 3), S112-S119 (1998).
2. National Kidney Foundation. K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease. Am. J. Kidney Dis. 41(Suppl. 3), S1-S92 (2003).
3. Kronenberg F, Utermann G, Dieplinger H. Lipoprotein(a) in renal disease. Am. J. Kidney Dis. 27, 1-25 (1996).
4. Kronenberg F, Neyer U, Lhotta K et al. The low-molecular-weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up. J. Am. Soc. Nephrol. 10, 1027-1036 (1999).
5. Loscalzo J, Weinfeld M, Fless GM, Scanu AM. Lipoprotein(a), fibrin binding, and plasminogen activation. Arteriosclerosis 10, 240-245 (1990).
6. Utermann G. Lipoprotein(a). In: The Metabolic and Molecular Bases of Inherited Disease, Eighth Edition. Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw-Hill, Il, USA, 2753-2787 (2000).
7. Utermann G, Menzel HJ, Kraft HG et al. Lp(a) glycoprotein phenotypes: inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J. Clin. Invest. 80, 458-465 (1987).
8. Kraft HG, Köchl S, Menzel HJ, Sandholzer C, Utermann G. The apolipoprotein(a) gene: a transcribed hypervariable locus controlling plasma lipoprotein(a) concentration. Hum. Genet. 90, 220-230 (1992).
9. Lackner C, Boerwinkle E, Leffert CC, Rahmig T, Hobbs HH. Molecular basis of apolipoprotein(a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis. J. Clin. Invest. 87, 2153-2161 (1991).
10. Utermann G. Genetic architecture and evolution of the lipoprotein(a) trait. Curr. Opin. Lipidol. 10, 133-141 (1999).
11. Krempler F, Kostner GM, Bolzano K, Sandhofer F. Turnover of lipoprotein(a) in man. J. Clin. Invest. 65, 1483-1490 (1980).
12. Rader DJ, Cain W, Zech LA, Usher D, Brewer HB Jr. Variation in lipoprotein(a) concentrations among individuals with the same apolipoprotein(a) isoform is determined by the rate of lipoprotein(a) production. J. Clin. Invest. 91, 443-447 (1993).
13. Kronenberg F, Trenkwalder E, Lingenhel A et al. Renovascular arteriovenous differences in Lp(a) plasma concentrations suggest removal of Lp(a) from the renal circulation. J. Lipid Res. 38, 1755-1763 (1997).
14. Oida K, Takai H, Maeda H et al. Apolipoprotein(a) is present in urine and its excretion is decreased in patients with renal failure. Clin. Chem. 38, 2244-2248 (1992).
15. Mooser V, Seabra MC, Abedin M et al. Apolipoprotein(a) kringle 4-containing fragments in urine. Relationship to plasma levels of lipoprotein(a). J. Clin. Invest. 97, 858-864 (1996).
16. Kostner KM, Maurer G, Huber K et al. Urinary excretion of apo(a) fragments. Role in apo(a) catabolism. Arterioscler. Thromb. Vasc. Biol. 16, 905-911 (1996).
17. Mooser V, Marcovina SM, White AL, Hobbs HH. Kringle-containing fragments of apolipoprotein(a) circulate in human plasma and are excreted into the urine. J. Clin. Invest. 98, 2414-2424 (1996).
18. Kronenberg F, König P, Neyer U et al. Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J. Am. Soc. Nephrol. 6, 110-120 (1995).
19. Kronenberg F, Utermann G. Lipoprotein(a). In: Encyclopedia of Endocrine Diseases. Martini L (Ed.), Academic Press, CA, USA, 188-196 (2004).
20. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease: meta-analysis of prospective studies. Circulation 102, 1082-1085 (2000).
21. Craig WY, Neveux LM, Palomaki GE, Cleveland MM, Haddow JE. Lipoprotein(a) as a risk factor for ischemic heart disease: meta-analysis of prospective studies. Clin. Chem. 44, 2301-2306 (1998).
22. Kronenberg F, Steinmetz A, Kostner GM, Dieplinger H. Lipoprotein(a) in health and disease. Crit. Rev. Clin. Lab. Sci. 33, 495-543 (1996).
23. Hopkins PN, Wu LL, Hunt SC et al. Lipoprotein(a) interactions with lipid and nonlipid risk factors in early familial coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 17, 2783-2792 (1997).
24. Foody JM, Milberg JA, Robinson K et al. Homocysteine and lipoprotein(a) interact to increase CAD risk in young men and women. Arterioscler. Thromb. Vasc. Biol. 20, 493-499 (2000).
25. Kronenberg F, Kronenberg MF, Kiechl S et al. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck Study. Circulation 100, 1154-1160 (1999).
26. Sandholzer C, Saha N, Kark JD et al. Apo(a) isoforms predict risk for coronary heart disease: a study in six populations. Arterioscler. Thromb. 12, 1214-1226 (1992).
27. Wild SH, Fortmann SP, Marcovina SM. A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five-City Project participants. Arterioscler. Thromb. Vasc. Biol. 17, 239-245 (1997).
28. Klausen IC, Sjol A, Hansen PS et al. Apolipoprotein(a) isoforms and coronary heart disease in men - a nested case-control study. Atherosclerosis 132, 77-84 (1997).
29. Grainger DJ, Kirschenlohr HL, Metcalfe JC et al. Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science 260, 1655-1658 (1993).
30. Grainger DJ, Kemp PR, Metcalfe JC et al. The serum concentration of active transforming growth factor-b is severely depressed in advanced atherosclerosis. Nature Med. 1, 74-79 (1995).
31. Takami S, Yamashita S, Kihara S et al. Lipoprotein(a) enhances the expression of intercellular adhesion molecule-1 in cultured human umbilical vein endothelial cells. Circulation 97, 721-728 (1998).
32. Syrovets T, Thillet J, Chapman MJ, Simmet T. Lipoprotein(a) is a potent chemoattractant for human peripheral monocytes. Blood 90, 2027-2036 (1997).
33. Poon M, Zhang XX, Dunsky KG, Taubman MB, Harpel PC. Apolipoprotein(a) induces monocyte chemotactic activity in human vascular endothelial cells. Circulation 96, 2514-2519 (1997).
34. Hervio L, Girard-Globa A, Durlach V, Anglés-Cano E. The antifibrinolytic effect of lipoprotein(a) in heterozygous subjects is modulated by the relative concentration of each of the apolipoprotein(a) isoforms and their affinity for fibrin. Eur. J. Clin. Invest. 26, 411-417 (1996).
35. Leerink CB, Duif PF, Verhoeven N et al. Apolipoprotein(a) isoform size influences binding of lipoprotein(a) to plasmin-modified des-AA-fibrinogen. Fibrinolysis 8, 214-220 (1994).
36. Dieplinger H, Lackner C, Kronenberg F et al. Elevated plasma concentrations of lipoprotein(a) in patients with end stage renal disease are not related to the size polymorphism of apolipoprotein(a). J. Clin. Invest. 91, 397-401 (1993).
37. Kronenberg F, Kuen E, Ritz E et al. Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. J. Am. Soc. Nephrol. 11, 105-115 (2000).
38. Sechi LA, Zingaro L, Catena C et al. Lipoprotein(a) and apolipoprotein(a) isoforms and proteinuria in patients with moderate renal failure. Kidney Int. 56, 1049-1057 (1999).
39. Kronenberg F, Lingenhel A, Lhotta K et al. The apolipoprotein(a) size polymorphism is associated with nephrotic syndrome. Kidney Int. 65, 606-612 (2004).
40. Wanner C, Rader D, Bartens W et al. Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome. Ann. Intern. Med. 119, 263-269 (1993).
41. Stenvinkel P, Berglund L, Heimbürger O, Pettersson E, Alvestrand A. Lipoprotein(a) in nephrotic syndrome. Kidney Int. 44, 1116-1123 (1993).
42. de Sain-van der Velden MG, Reijngoud DJ, Kaysen GA et al. Evidence for increased synthesis of lipoprotein(a) in the nephrotic syndrome. J. Am. Soc. Nephrol. 9, 1474-1481 (1998).
43. Kronenberg F, König P, Lhotta K et al. Apolipoprotein(a) phenotype-associated decrease in lipoprotein(a) plasma concentrations after renal transplantation. Arterioscler. Thromb. 14, 1399-1404 (1994).
44. Stenvinkel P, Heimbürger O, Tuck CH, Berglund L. Apo(a)-isoform size, nutritional status and inflammatory markers in chronic renal failure. Kidney Int. 53, 1336-1342 (1998).
45. Milionis HJ, Elisaf MS, Tselepis A et al. Apolipoprotein(a) phenotypes and lipoprotein(a) concentrations in patients with renal failure. Am. J. Kidney Dis. 33, 1100-1106 (1999).
46. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 55, 648-658 (1999).
47. Parsons DS, Reaveley DA, Pavitt DV, Brown EA. Relationship of renal function to homocysteine and lipoprotein(a) levels: the frequency of the combination of both risk factors in chronic renal impairment. Am. J. Kidney Dis. 40, 916-923 (2002).
48. Kerschdorfer L, König P, Neyer U et al. Lipoprotein(a) plasma concentrations after renal transplantation: a prospective evaluation after 4 years of follow-up. Atherosclerosis 144, 381-391 (1999).
49. Kronenberg F, Lhotta K, König P et al. Apolipoprotein(a) isoform-specific changes of lipoprotein(a) after kidney transplantation. Eur. J. Hum. Genet. 11, 693-699 (2003).
50. Appel GB, Blum CB, Chien S, Kunis CL, Appel AS. The hyperlipidemia of nephrotic syndrome: relation to plasma albumin concentration, oncotic pressure and viscosity. N. Engl. J. Med. 312, 1544-1548 (1985).
51. Heimbürger O, Stenvinkel P, Berglund L, Tranæus A, Lindholm B. Increased plasma lipoprotein(a) in continuous ambulatory peritoneal dialysis is related to peritoneal transport of proteins and glucose. Nephron 72, 135-144 (1996).
52. Yang WS, Min WK, Park JS, Kim SB. Effect of increasing serum albumin on serum lipoprotein(a) concentration in patients receiving CAPD. Am. J. Kidney Dis. 30, 507-513 (1997).
53. Stenvinkel P. Interactions between inflammation, oxidative stress, and endothelial dysfunction in end stage renal disease. J. Ren. Nutr. 13, 144-148 (2003).
54. Kang DH, Yoon KI, Lee SW et al. Impact of nutritional status on serum lipoprotein(a) concentration in patients undergoing continuous ambulatory peritoneal dialysis. Perit. Dial. Int. 16(Suppl. 1), S241-S245 (1996).
55. Stenvinkel P, Heimbürger O, Paultre F et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 55, 1899-1911 (1999).
56. Longenecker JC, Klag MJ, Marcovina SM et al. Small apolipoprotein(a) size predicts mortality in end stage renal disease: the CHOICE Study. Circulation 106, 2812-2818 (2002).
57. Emanuele E, Lusignani LS, Peros E et al. Lipoprotein(a)-associated atherothrombotic risk in hemodialysis patients. Am. J. Nephrol. 24, 221-229 (2004).
58. Parsons DS, Reaveley DA, Pavitt DV, Misra M, Brown EA. Lipoprotein(a) levels in those with high-molecular-weight apo(a) isoforms may remain low in a significant proportion of patients with end stage renal disease. Nephrol. Dial. Transplant. 18, 1848-1853 (2003).
59. Fleischmann EH, Bower JD, Salahudeen AK. Are conventional cardiovascular risk factors predictive of 2-year mortality in hemodialysis patients? Clin. Nephrol. 56, 221-230 (2001).
60. Koda Y, Nishi S, Suzuki M, Hirasawa Y. Lipoprotein(a) is a predictor for cardiovascular mortality of hemodialysis patients. Kidney Int. 56(Suppl. 71), S251-S253 (1999).
61. Ohashi H, Oda H, Ohno M, Watanabe S, Sakata S. Lipoprotein(a) as a risk factor for coronary artery disease in hemodialysis patients. Kidney Int. 56(Suppl. 71), S242-S244 (1999).
62. Benedetto FA, Mallamaci F, Tripepi G, Zoccali C. Prognostic value of ultrasonographic measurement of carotid intima media thickness in dialysis patients. J. Am. Soc. Nephrol. 12, 2458-2464 (2001).
63. Koch M, Kutkuhn B, Grabensee B, Ritz E. Apolipoprotein A, fibrinogen, age, and history of stroke are predictors of death in dialysed diabetic patients: a prospective study in 412 subjects. Nephrol. Dial. Transplant. 12, 2603-2611 (1997).
64. Cressman MD, Heyka RJ, Paganini EP et al. Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 86, 475-482 (1992).
65. Geroldi D, Bellotti V, Buscaglia P et al. Characterization of apo(a) polymorphism by a modified immunoblotting technique in an Italian population sample. Clin. Chim. Acta 221, 159-169 (1993).
66. Avram MM, Sreedhara R, Patel N et al. Is an elevated level of serum lipoprotein(a) a risk factor for cardiovascular disease in CAPD patients? Adv. Perit. Dial. 12, 266-271 (1996).
67. Koch M, Gradaus F, Schoebel F-C, Leschke M, Grabensee B. Relevance of conventional cardiovascular risk factors for the prediction of coronary artery disease in diabetic patients on renal replacement therapy. Nephrol. Dial. Transplant. 12, 1187-1191 (1997).
68. Iliescu EA, Marcovina SM, Morton AR, Lam M, Koschinsky ML. Apolipoprotein(a) phenotype and lipoprotein(a) level predict peritoneal dialysis patient mortality. Perit. Dial. Int. 22, 492-499 (2002).
69. Koch M, Kutkuhn B, Trenkwalder E et al. Apolipoprotein B, fibrinogen, HDL-cholesterol and apolipoprotein(a) phenotypes predict coronary artery disease in hemodialysis patients. J. Am. Soc. Nephrol. 8, 1889-1898 (1997).
70. Güz G, Özdemir FN, Sezer S et al. Effect of apolipoprotein E polymorphism on serum lipid, lipoproteins, and atherosclerosis in hemodialysis patients. Am. J. Kdney Dis. 36, 826-836 (2000).
71. Shoji T, Nishizawa Y, Kawagishi T et al. Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients. J. Am. Soc. Nephrol. 9, 1277-1284 (1998).
72. Webb AT, Reaveley DA, O'Donnell M et al. Lipids and lipoprotein(a) as risk factors for vascular disease in patients on renal replacement therapy Nephrol. Dial. Transplant. 10, 354-357 (1995).
73. Kronenberg F, Kathrein H, König P et al. Apolipoprotein(a) phenotypes predict the risk for carotid atherosclerosis in patients with end stage renal disease. Arterioscler. Thromb. 14, 1405-1411 (1994).
74. Gazzaruso C, Bonetti G, Garzaniti A et al. Increased plasma concentrations of tipoprotein(a) for every phenotype of apolipoprotein(a) in patients with chronic renal failure treated by hemodialysis. Nutr. Metab. Cardiovasc. Dis. 6, 203-210 (1996).
75. Kimura K, Saika Y, Otani H et al. Factors associated with calcification of the abdominal aorta in hemodialysis patients. Kidney Int. 56(Suppl. 71), S238-S241 (1999).
76. Oishi Y, Nagake Y, Yamasaki H et al. The significance of atherogenic indices in patients on hemodialysis. Am. J. Nephrol. 20, 107-115 (2000).
77. Gault MH, Longerich LL, Purchase L, Harnett J, Breckenridge C. Comparison of Lp(a) concentrations and some potential effects in hemodialysis, CAPD, transplantation, and control groups, and review of the literature. Nephron 70, 155-170 (1995).
78. Lye WC, Hughes Y, Leong SO, Lee EJ. Lipoprotein(a) levels and clinical correlations in CAPD patients. Adv. Perit. Dial 11, 131-133 (1995).
79. Auguet T, Sentí M, Rubies-Prat J et al. Serum lipoprotein(a) concentration in patients with chronic renal failure receiving hemodialysis: influence of apolipoprotein(a) genetic polymorphism. Nephrol. Dial. Transplant. 8, 1099-1103 (1993).
80. Docci D, Manzoni G, Bilancioni R et al. Serum lipoprotein(a) and coronary artery disease in uremic patients on chronic hemodialysis. Int. J. Artif. Organs 17, 41-45 (1994).
81. Wanner C, Bartens W, Walz G, Nauck M, Schollmeyer P. Protein loss and genetic polymorphism of apolipoprotein(a) modulate serum lipoprotein(a) in CAPD patients. Nephrol. Dial. Transplant. 10, 75-81 (1995).
82. Kronenberg F, Mündle M, Längle M, Neyer U. Prevalence and progression of peripheral arterial calcifications in patients with ESRD. Am. J. Kidney Dis. 41, 140-148 (2003).
83. Longenecker JC, Coresh J, Marcovina SM et al. Lipoprotein(a) and prevalent cardiovascular disease in a dialysis population: the Choices for Healthy Outcomes In Caring for ESRD (CHOICE) study. Am. J. Kidney Dis. 42, 108-116 (2003).
84. Kronenberg F. Lipoprotein(a) in renal disease: what we have, what we need, what we can forget. Nephrol. Dial. Transplant. 10, 766-769 (1995).
85. Teplan V, Schuck O, Stollova M, Vitko S. Obesity and hyperhomocysteinemia after kidney transplantation. Nephrol. Dial. Transplant. 18(Suppl. 5), V71-V73 (2003).
86. Lye WC, Hughes K, Leong SO, Tan CC, Lee EJC. Abnormal lipoprotein(a) and lipid profiles in renal allograft recipients: effects of treatment with pravastatin. Tranplant. Proc. 27, 977-978 (1995).
87. Castro R, Queirós J, Fonseca I et al. Therapy of post-renal transplantation hyperlipidemia: comparative study of simvastatin and fish oil. Nephrol. Dial. Transplant. 12, 2140-2143 (1997).
88. Nishikawa O, Mune M, Miyano M et al. Effect of simvastin on the lipid profile of hemodialysis patients. Kidney Int. 56(Suppl. 71), S219-S221 (1999).
89. Wanner C, Bohler J, Eckardt HG, Wieland H, Schollmeyer P. Effects of simvastatin on lipoprotein(a) and lipoprotein composition in patients with nephrotic syndrome. Clin. Nephrol. 41, 138-143 (1994).
90. Traindl O, Reading S, Franz M et al. Treatment of hyperlipidemic kidney graft recipients with lovastatin: effect on LDL-cholesterol and lipoprotein(a). Nephron 62, 394-398 (1992).
91. Li PKT, Mak TWL, Chiu K et al. Effect of lovastatin on serum lipid profile in the treatment of dyslipoproteinemia in uremic patients on continuous ambulatory peritoneal dialysis. Aust. NZ. J. Med. 23, 252-257 (1993).
92. Türk S, Yildiz A, Tükek T et al. The effect of fluvastatin of hyperlipidemia in renal transplant recipients: a prospective, placebo-controlled study. Int. Urol. Nephrol. 32, 713-716 (2001).
93. Podder H, Gero I, Földes K et al. Treatment of metabolic disorders with fluvastatin after renal transplantation. Transplant. Troc. 29, 216-219 (1997).
94. Li PKT, Mak TWL, Clian TH et al. Effect of fluvastatin on lipoprotein profiles in treating renal transplant recipients with dyslipoproteineimia. Transplantation 60, 652-656 (1995).
95. Samuelsson O, Attman PO, Knight-Gibson C et al. Fluvastatin improves lipid abnormalities in patients with moderate to advanced chronic renal insufficiency. Am. J. Kidney Dis. 39, 67-75 (2002).
96. Krmar RT, Ferraris JR, Ramirez JA et al. Use of atorvastatin in hyperlipidemic hypertensive renal transplant recipients. Pediatr. Nephrol. 17, 540-543 (2002).
97. Navarro JF, Mora C, Muros M, Garcia-Idoate G. Effects of atorvastatin on lipid profile and nontraditional cardiovascular risk factors in diabetic patients on hemodialysis. Nephron Clin. Pract. 95, C128-C135 (2003).
98. Irish AB, Thompson CH. The effects of gemfibrozil upon the hypercoagulable state in dyslipidemic patients with chronic renal failure. Nephrol. Dial. Transplant. 11, 2223-2228 (1996).
99. Pelegrí A, Romero R, Sentí M et al. Effect of bezafibrate on lipoprotein(a) and triglyceride-rich lipoproteins, including intermediate-density lipoproteins, in patients with chronic renal failure receiving hemodialysis. Nephrol. Dial. Transplant. 7, 623-626 (1992).
100. McKenney J. New perspectives on the use of niacin in the treatment of lipid disorders. Arch. Intern. Med. 164, 697-705 (2004).
101. Carlson LA, Hamsten A, Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidemic subjects treated with nicotinic acid. J. Intern. Med. 226, 271-276 (1989).
102. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106, 3143-3421 (2002).
103. Yamauchi K, Tanahashi Y, Okada M et al. Long-term effects of niceritrol on serum lipoprotein(a) and lipids in patients with high levels of lipoprotein(a). Clin. Ther. 17, 52-59 (1995).
104. Kinoshita M, Mikuni Y, Kudo M et al. The effects of combination therapy with niceritrol and pravastatin on hyperlipidemia. J. Int. Med. Res. 30, 271-281 (2002).
105. Superko HR, Krauss RM. Differential effects of nicotinic acid in subjects with different LDL subclass patterns. Atherosclerosis 95, 69-76 (1992).
106. Rosenson RS. Antiatherothrombotic effects of nicotinic acid. Atherosclerosis 171, 87-96 (2003).
107. Canner PL, Berge KG, Wenger NK et al. 15 year mortality in Coronary Drug Project patients: long-term benefit with niacin. J. Am. Coll. Cardiol. 8, 1245-1255 (1986).
108. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med. Scand. 223, 405-418 (1988).
109. Nakahama H, Nakanishi T, Uyama O et al. Niceritrol reduces plasma lipoprotein(a) levels in patients undergoing maintenance hemodialysis. Ren. Fail. 15, 189-193 (1993).
110. Shoji T, Nishizawa Y, Kawasaki K et al. Effects of the nicotinic acid analog niceritrol on lipoprotein Lp(a) and coagulation-fibrinolysis status in patients with chronic renal failure on hemodialysis. Nephron 77, 112-113 (1997).
111. Mavromatidis K, Fitili C, Sombolos K. Can acipimox reduce serum lipoprotein(a) levels in hemodialyzed patients? Nephron 78, 489 (1998).
112. Owada A, Suda S, Hata T. Antiproteinuric effect of niceritrol, a nicotinic acid derivative, in chronic renal disease with hyperlipidemia: a randomized trial. Am. J. Med. 114, 347-353 (2003).
113. Berg AL, Nilsson-Ehle P. ACTH lowers serum lipids in steroid-treated hyperlipidemic patients with kidney disease. Kidney Int. 50, 538-542 (1996).
114. Berg AL, Nilsson-Ehle P, Arnadottir M. Beneficial effects of ACTH on the serum lipoprotein profile and glomerular function in patients with membranous nephropathy. Kidney Int. 56, 1534-1543 (1999).
115. Arnadottir M, Berg A-L, Kronenberg F et al. Corticotropin-induced reduction of plasma lipoprotein(a) concentrations in healthy individuals and hemodialysis patients: relation to apolipoprotein(a) size polymorphism. Metabolism 48, 342-346 (1999).
116. Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein(a) concentrations: analysis of studies published from 1974-2000. Fertil. Steril. 75, 898-915 (2001).
117. Ginsburg ES, Walsh B, Greenberg L et al. Effects of estrogen replacement therapy on the lipoprotein profile in postmenopausal women with ESRD. Kidney Int. 54, 1344-1350 (1998).
118. Park JS, Jung HH, Yang WS et al. Effects of hormonal replacement therapy on lipid and hemostatic factors in postmenopausal ESRD patients. Nephrol. Dial. Transplant. 15, 1835-1840 (2000).
119. Kostner GM, Ibovnik A, Holzer H, Grillhofer H. Preparation of a stable fresh frozen primary lipoprotein(a) (Lp[a]) standard. J. Lipid Res. 40, 2255-2263 (1999).
120. Marcovina SM, Albers JJ, Scanu AM et al. Use of a reference material proposed by the international federation of clinical chemistry and laboratory medicine to evaluate analytical methods for the determination of plasma lipoprotein(a). Clin. Chem. 46, 1956-1967 (2000).
121. Kronenberg F, Lingenhel A, Lhotta K et al. Lipoprotein(a)- and low-density lipoprotein-derived cholesterol in nephrotic syndrome: impact on lipid-lowering therapy?. Kidney Int. 66, 348-354 (2004).
122. Kronenberg F, Lingenhel A, Neyer U et al. Prevalence of dyslipidemic risk factors in hemodialysis and CAPD patients. Kidney Int. 63(Suppl. 84), S113-S114 (2003).
123. Kostner GM, Gavish D, Leopold B et al. HMG CoA reductase inhibitors lower LDL-cholesterol without reducing Lp(a) levels. Circulation 80, 1313-1319 (1989).
124. Scanu AM, Hinman J. Issues concerning the monitoring of statin therapy in hypercholesterolemic subjects with high plasma lipoprotein(a) levels. Lipids 37, 439-444 (2002).
125. Brown CD, Azrolan N, Thomas L et al. Reduction of lipoprotein(a) following treatment with lovastatin in patients with unremitting nephrotic syndrome. Am. J. Kidney Dis. 26, 170-177 (1995).